Showing results (21-30 of 81) with videos related to

Sort By:
Pageof 9
The Journal of Experimental Medicine|June 22, 2011
Sustained antibody responses depend on CD28 function in bone marrow-resident plasma cellsCheryl H Rozanski, Ramon Arens, Louise M Carlson, et al.
The Lancet. Haematology|September 30, 2017
Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trialAsher A Chanan-Khan, Andrey Zaritskey, Miklos Egyed, et al.
Future Oncology (London, England)|June 6, 2014
The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemiaMichael Hallek, Neil E Kay, Anders Osterborg, et al.
The Journal of Supportive Oncology|January 7, 2012
Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patientsAbhisek Swaika, Aneel Paulus, Kena C Miller, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|May 29, 2019
Survival trends in glioblastoma and association with treating facility volumeSonikpreet Aulakh, Michelle R DeDeo, Joseph Free, et al.
Hematological Oncology|April 30, 2022
Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial resultsSikander Ailawadhi, Ricardo D Parrondo, Muhamad Alhaj Moustafa, et al.
Leukemia & Lymphoma|April 7, 2010
Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysisRachid Baz, Mehul Patel, Elizabeth Finley-Oliver, et al.
British Journal of Haematology|May 4, 2011
Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 studyPaul G Richardson, Asher A Chanan-Khan, Sagar Lonial, et al.
Leukemia & Lymphoma|April 18, 2009
Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myelomaAsher A Chanan-Khan, Ruben Niesvizky, Raymond J Hohl, et al.
Blood|December 2, 2006
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective studyAsher A Chanan-Khan, Jonathan L Kaufman, Jayesh Mehta, et al.
Pageof 9